Phathom Pharmaceuticals advertising spend, FY2025

Phathom Pharmaceuticals (PHAT) reported $61.3M of marketing and advertising expense for the fiscal year ended Dec 31, 2025. It does not tag advertising separately, so this broader figure stands in for it. That is 35.0% of revenue of $175M. Up 0.0% from FY2024.

Marketing and advertising, FY2025
$61.3M
year ended Dec 31, 2025
Change vs prior year
0.0%
vs FY2024
Share of revenue
35.0%
of $175M revenue
Rank by ad spend
#425
of 458 companies

Key facts

  • Ad spend is 1.0x its FY2024 level ($61.3M), slower than revenue (3.2x).
  • Phathom Pharmaceuticals's marketing and advertising expense is higher than the figure of 7% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 7.7x the median of 4.5%.

Ad spend by fiscal year

$0 $20M $40M $60M $80M FY2024 (ended 2024-12-31): $61.3M 2024 FY2025 (ended 2025-12-31): $61.3M 2025 $61.3M

Ad spend as % of revenue

0% 50% 100% 150% FY2024 (ended 2024-12-31): 110.9% 2024 FY2025 (ended 2025-12-31): 35.0% 2025 35.0%

Ad spend in context, FY2025

Advertising was 21.9% of selling, general and administrative expense. Advertising was 1.9x research and development spending. The company reported an operating loss of $160M.

Advertising $61.3M MarketingAndAdvertisingExpense
Selling, general and administrative $280M ad spend = 21.9%
Research and development $32.8M ad spend = 1.9x R&D
Operating loss -$160M
Net loss -$221M

Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.

History

Download CSV
Fiscal year Period end Ad spend YoY Revenue Ad / revenue Tag Filing
FY2025 Dec 31, 2025 $61.3M 0.0% $175M 35.0% MarketingAndAdvertisingExpense 10-K Feb 26, 2026
FY2024 Dec 31, 2024 $61.3M n/a $55.3M 110.9% MarketingAndAdvertisingExpense 10-K Feb 26, 2026

Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.

What the figure is

Marketing and advertising combined, as reported under the XBRL tag MarketingAndAdvertisingExpense. It is broader than advertising alone.

Compared with similar spenders

The 6 companies closest to Phathom Pharmaceuticals in latest-year ad spend.

Rank Company Ad spend Ad / revenue YoY Fiscal year
420 Boot Barn $62.8M 2.8% +24.4% FY2026
421 Open Text $62.3M 1.2% -3.9% FY2026
422 Illinois Tool Works $62M 0.4% +6.9% FY2025
423 Phillips 66 $62M 0.05% +21.6% FY2025
424 Simply Good Foods $62M 4.6% -18.5% FY2026
425 Phathom Pharmaceuticals $61.3M 35.0% 0.0% FY2025
426 Trex $61M 5.2% +14.0% FY2025

Full ranking of 458 companies · Highest ad-to-revenue #14 · More on ads than R&D #66 · Ads above operating profit #148

Questions

How much does Phathom Pharmaceuticals spend on advertising?

Phathom Pharmaceuticals does not report advertising separately. Its marketing and advertising expense was $61.3M in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 26, 2026. That figure is broader than advertising.

What percentage of revenue does Phathom Pharmaceuticals spend on advertising?

35.0% of revenue in fiscal 2025 ($61.3M of marketing and advertising expense against $175M). The median across the 458 companies tracked is 4.5%.

Is Phathom Pharmaceuticals spending more on advertising?

Yes. Ad spend rose 0.0% in fiscal 2025 from fiscal 2024.

How does Phathom Pharmaceuticals rank by advertising spend?

#425 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.

Does Phathom Pharmaceuticals spend more on advertising than on R&D?

Yes. In fiscal 2025 it spent $61.3M on advertising and $32.8M on research and development.

What does Phathom Pharmaceuticals's advertising figure include?

Marketing and advertising combined, as reported under the XBRL tag MarketingAndAdvertisingExpense. It is broader than advertising alone.

Company and source

Filing
10-K for FY2025, filed Feb 26, 2026
Accession number
0001193125-26-073379
Company
Phathom Pharmaceuticals, Inc., CIK 1783183, SIC 2834 (Pharmaceutical Preparations)
Headquarters
Florham Park, NJ
Incorporated in
DE
Fiscal year ends
December 31
Listed on
Nasdaq
SEC filer status
Non-accelerated filer, Smaller reporting company
Data
SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
Cite
Phathom Pharmaceuticals advertising spend, FY2024-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 26, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/phathom-pharmaceuticals/advertising-spend/
Download
CSV, all years · CSV, all 458 companies